Media - Singapore Press Release
Arrayit awarded multi-patient genotyping patent in Singapore.
Sunnyvale, CA, October 28, 2005 – On September 30th, Arrayit was awarded a patent for multi-patient genotyping technology from the Intellectual Property Office of Singapore. Wong Sheng Kwai, Acting Registrar of Patents from the Registry of Patents Singapore, signed the Certificate of Grant of Patent, granting TeleChem International patent protection on its invention entitled “Microarray Method of Genotyping Multiple Patients at Multiple Loci”. Earlier this year, the United States Patent and Trademark office issued U.S. patent 6,913,879 on the same invention, but Singapore is the first foreign entity to grant patent protection on TeleChem International’s multi-patient technology. Singapore Patent Number 94899 grants the company patent protection for its methods of genotyping many patients at once. In a preferred embodiment, patient samples are amplified by the polymerase chain reaction, configured into microarrays, hybridized with fluorescent oligonucleotides, and genotyped by reading the microarray signals. Because the patient DNA forms the microarray, as many as 100,000 patients can be genotyped in a single hybridization reaction. Multi-patient technology greatly reduces the cost of patient genotyping compared to traditional “single patient” techniques, and the company is currently offering multi-patient genotyping products and services via its Diagnostics Division.
Company President Rene’ Schena shared her thoughts on the Singapore patent. “We were delighted to learn of the issuance of our Singapore patent. Together with our U.S. patent, the Singapore patent allows us to begin commercializing genetic screens and tests in Southeast Asia, a very exciting market for us. We see a lot of opportunities in Signapore, a biotechnology hub in Southeast Asia. We appreciate the diligence of the IPOS in evaluating our intellectual property.”
TeleChem International is a privately owned high-tech company located in the heart of California’s Silicon Valley. Our products and services are provided by three corporate divisions: ArrayIt® Life Sciences Division, Chemicals Division, and a Diagnostics Division. The ArrayIt® Life Sciences Division offers a complete microarray technology platform that empowers >10,000 laboratories to use microarrays for human genome exploration, basic research, drug discovery, and myriad life sciences applications. Nearly every major research institution uses our patented microarray manufacturing technology (U.S. 6,101,946) and supporting products and services. The Chemicals Division provides import and export services and government contract manufacturing in the area of industrial chemicals for plastics, fire control, water treatment, agriculture, industrial and institutional compounding, and green energy. The Diagnostics Division holds key patents in the United States (6,913,879), Singapore (94899), New Zealand (523560), and other countries for its revolutionary “multi-patient” genotyping technology, which allows as many as 100,000 patients to be tested on a single microarray. Arrayit Diagnostics enables genotyping and disease diagnostics by providing testing kits, services, and technology transfer opportunities for disease screening and testing organizations.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.